Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients

@article{Rdel2007IntegrationON,
  title={Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients},
  author={Claus Michael R{\"o}del and Rolf Sauer},
  journal={Strahlentherapie und Onkologie},
  year={2007},
  volume={183},
  pages={227-235}
}
With optimized local treatment – achieved through preoperative radiochemotherapy (RCT) and total mesorectal excision (TME) surgery – distant metastases are by far the predominate sites of tumor failure in rectal cancer today. The challenge is to integrate more effective systemic therapy into combined-modality programs. Capecitabine, oxaliplatin, irinotecan as well as targeted therapies improved results for colorectal cancer patients when treated in the metastatic and adjuvant setting. These… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: a planning study with clinical implications.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2012
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 81 references

The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis

J Giralt, M de las Heras, L Cerezo
Radiother Oncol 2005;74:101–8 • 2005
View 7 Excerpts
Highly Influenced

Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.

International journal of radiation oncology, biology, physics • 2006
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…